E. Jiménez-Aguilar

发表

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

J. Heymach, M. Hellmann, M. Nishino, 2020, Journal for ImmunoTherapy of Cancer.

Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti–PD-1 for patients with anti–PD-1–refractory tumors

I. Melero, M. Rodriguez-Ruiz, P. López-Casas, 2020, Science Translational Medicine.

Rechallenge with Immunotherapy in Small Cell Lung Cancer – A Case Report

L. Paz-Ares, S. Ponce-Aix, Helena S Gouveia, 2019 .

An unsuspected complication with immune checkpoint blockade: a case report

C. Díaz-Pedroche, C. Gómez-Martín, E. Jiménez-Aguilar, 2018, Journal of Medical Case Reports.

Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.

N. Schultz, P. Jänne, E. V. Van Allen, 2019, JCO precision oncology.

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

J. Heymach, M. Hellmann, M. Nishino, 2020, Journal for ImmunoTherapy of Cancer.

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

L. Paz-Ares, V. Calvo, C. Font, 2020, European journal of cancer.

Lurbinectedin in the treatment of relapsed small cell lung cancer.

L. Paz-Ares, V. Alfaro, C. Kahatt, 2021, Future Oncology.

OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial

L. Paz-Ares, C. Kahatt, G. Cote, 2021 .